BioCatalyst

DNLI — Denali Therapeutics Inc. catalysts

2 verified catalyst event(s) for Denali Therapeutics Inc. (ticker DNLI). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2026-12-01 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DN · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 27d
ESTIMATED
 READOUT
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyna
Phase 1/2 · Frontotemporal Dementia
 DNLI Denali Therapeutics Inc. DNL593 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2027-03 (month)
in 4mo
ESTIMATED
 READOUT
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associa
Phase 2 · Parkinson Disease
 DNLI Denali Therapeutics Inc. BIIB122 225 mg, BIIB122-Matching Placebo ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.